Compounds / FDA approved

4 of 23 are FDA approved

Approval is narrow and specific. A compound approved for one condition in one population is not approved for everything it is marketed for — that gap is where most confusion lives. Each entry below states what the approval actually covers.

PT-141
Bremelanotide · Vyleesi
Genuinely approved — as Vyleesi, for one specific condition in premenopausal women. What is sold as "PT-141" online is not that product.
Pre
P1
P2
P3
10
Human trials
Tesamorelin
Egrifta
Genuinely FDA-approved — for one specific condition in people with HIV. That approval does not extend to the general anti-aging use it's sold for.
Pre
P1
P2
P3
21
Human trials
Tirzepatide
Mounjaro · Zepbound
The other yardstick. When something works, the trial record looks like this — not like a blank page.
Pre
P1
P2
P3
234
Human trials
Semaglutide
Ozempic · Wegovy
What a well-evidenced compound looks like: dozens of trials, Phase 3 and 4, approved indications that match what it's sold for. Included as the yardstick.
Pre
P1
P2
P3
610
Human trials
Read this
Approved for what, exactly
Read the specific indication on each compound page. Tesamorelin is approved for HIV-associated lipodystrophy, not general fat loss. Bremelanotide is approved as Vyleesi for one condition in premenopausal women. The distinction matters.

See all 23 compounds →